Age (years) | 42.0±9.9 |
Male | 140 (71.1) |
Weight (kg) | 54 (48–66) |
Current smoker | 107 (54.3) |
Diabetes mellitus type 2 | 40 (20.3) |
Pulmonary cavities | 78 (39.6) |
Extensive pulmonary disease | 38 (19.3) |
Severe disease | 56 (28.4) |
Time to positivity (days) | 11.9±3.0 |
Drug susceptibility profile | |
MDR-TB alone | 160 (81.2) |
Pre-XDR-TB | 37 (18.8) |
Drug intake (mg·kg−1) | |
Levofloxacin (500 mg, once daily) | 7.7 (6.7–8.4) |
Moxifloxacin (400 mg, once daily) | 8.6 (7.2–10.4) |
Linezolid (600 mg, once daily) | 11.3 (9.2–12.8) |
Bedaquiline (400 mg, once daily) | 7.5 (6.2–8.3) |
Clofazimine (100 mg, once daily)# | 9.3 (7.6–10.4) |
Cycloserine (500 mg, twice daily) | 3.8 (3.2–4.3) |
Prothionamide (600 mg, three times a day) | 10.8 (9.3–12.0) |
Pyrazinamide (1500 mg, three times a day) | 26.8 (21.7–30.0) |
Ethambutol (750 mg, once daily) | 13.9 (11.3–15.6) |
Number of drugs¶ in | |
Group A | 2.0±0.6 |
Group B | 1.6±0.5 |
Group C | 2.0±1.1 |
Effective drugs | 5.6±0.7 |
2-month culture conversion | 88 (44.7) |
6-month culture conversion | 128 (65.0) |
Time to culture conversion (months) | 4 (2–14) |
Treatment outcome | |
Success | 156 (79.2) |
Failure | 38 (19.3) |
Death | 1 (0.5) |
Lost to follow-up | 2 (1.0) |